Comparative Evaluation of the propertieS of the Contact LAyer Dressing LOMatuell Pro® Versus UrgoTul® in the Management of Acute Wounds

Acute Wounds Clinical Trial

— SLALOM  

Official title:

Comparative Evaluation of the propertieS of the Contact LAyer Dressing LOMatuell Pro® Versus UrgoTul® in the Management of Acute Wounds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03897465
• Other study ID #: 2018-A02288-47
• Status: Completed
• Phase: N/A
• Start date: February 11, 2019
• Est. completion date: December 6, 2020

Study information

• Verified date: December 2022
• Source: Lohmann & Rauscher
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparative evaluation of the propertieS of the contact LAyer dressing LOMatuell Pro® versus UrgoTul® in the management of acute wounds

Description:

National, multicenter, prospective, randomized in parallel groups, non-inferiority, open-label investigation study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 183
• Est. completion date: December 6, 2020
• Est. primary completion date: December 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute wound: traumatic wound (dermabrasion, skin tears, other), small burns 1st and 2nd degree requiring the use of dressings
• Acute wound size between 3 cm² and 24 cm² (wound could be covered by 2 investigational products maximum)
• Wound whose duration is = 3 days
• Both gender with an age = 18 years
• Written confirmation from the study nurse that the patient was informed, orally agreed to participate and to comply with study treatment and planned visits
• Subject able to follow the protocol

Exclusion Criteria:

• Chronic and acute surgical wound
• Infected, moderately to strongly exudative and haemorrhagic wound
• Diagnosed underlying disease (e.g. diabetic neuropathy, stroke, etc.) which as judged by the investigator could interfere with the pain assessment
• Known allergy/hypersensitivity to any of the components of the investigational products
• Participation in other clinical investigation within one month prior to start of investigation
• Pregnant or breast-feeding women
• Person protected by a legal regime (tutorship or guardianship)
• Patients unable to manifest an oral consent to participate (e.g. dementia) or to understand the use of the VAS tool
• Patient not covered by health insurance/social security

Related Conditions & MeSH terms

• Acute Wounds
• Wounds and Injuries

Intervention

Device:
• Lomatuell Pro
Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
• UrgoTul
Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.

Locations

Country	Name	City	State
France	CICA+	Limonest

Sponsors (2)

Lead Sponsor	Collaborator
Lohmann & Rauscher	RCTs

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of wound dressing changes associated with a pain <30 mm on Visual Analog Scale (VAS)	A specific ruler will be provided to the investigator in order to measure the VAS score. The subject will mark on the ruler the point that he/she feels represent his/her perception of his/her current pain. The VAS score will be directly measured by the investigator with a scale in millimetres. The VAS score will be filled in the CRF.	At Visit 2 (Day 3 ± 2 days)
Secondary	Complete healing: Percentage of epithelialization of the wound at V3 calculated based on a blind assessment from photographs using W.H.A.T. assessment		At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Condition of the wound	The wound bed condition will be evaluated regarding 6 condition items: bleeding, maceration, inflammation, infection, ratio necrotic/ fibrinous/ granulation/ epithelisation tissue, and tissue in-growth in the dressing holes, by means of the following 4-points scale: none, mild, moderate, severe. The percentage of each modality for each condition items will be calculated.	At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Condition of the surrounding skin	The condition of the surrounding skin will be assessed regarding different conditions: inflammatory signs, irritation, allergic rash/eczema, blistering, skin stripping, maceration, dry, trauma to wound edges, product degradation on the skin, hematoma, other. These condition items will be assessed by means of the scale Yes/No. The percentage of each modality will be calculated.	At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Global assessment of exudate management	This will use a Cochran-Mantel-Haenszel test including treatment groups and baseline wound exudation status (none, light and moderate/heavy).	At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Investigator's global assessment of the product	The global assessment of the dressing will be performed by the investigator regarding the following items: ease of handling, ability to maintain its integrity, ease of application, ability to be repositioned during application, conformability, wound adhesion, ability of dressings to stay in place, transparency, ability to transfer wound fluid to the secondary dressing, ease / speed of removal, overall impression, and absence of residue.; Each item will be evaluated by means of the following scale: very good, good, poor, and very poor.; The percentage of each modality will be presented.	At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Patient's global assessment of the product	The global assessment of the dressing will be performed by the subject regarding the following items: ability to maintain its integrity, ability of dressings to stay in place, transparency, comfort of the patient, ability to transfer wound fluid to the secondary dressing, ease/speed of removal, overall impression.; Each item will be evaluated by means of the following scale: very good, good, moderate, poor, very poor.; The percentage of each modality will be presented.	At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Secondary	Safety endpoint: frequency and character of device deficiencies (DDs), adverse events (AEs), serious adverse events (SAEs), adverse device effects (ADEs), serious adverse device effects (SADEs)	Safety analyses will be descriptive overall and by dressing group. Any local and general adverse events occurring and those already present, but worsening, during the course of the investigation will be described on the safety population. Frequencies will be provided per dressing group and overall describing the type of event: device deficiency (DD), adverse event (AE), serious AE (SAE), adverse device effect (ADE), serious ADE	At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)